Leukemia Clinical Trials in Cáceres
8 recruitingCáceres, Spain
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled238 locationsNCT06852222
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled73 locationsNCT04256317
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Acute Myeloid Leukemias
Syndax Pharmaceuticals76 enrolled46 locationsNCT06226571
Recruiting
Phase 1Phase 2
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMyelodysplastic Syndrome/Acute Myeloid Leukemia
AB Science78 enrolled10 locationsNCT05211570
Recruiting
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Acute Myeloid Leukemia
Ryvu Therapeutics SA98 enrolled37 locationsNCT06191263
Recruiting
Phase 1Phase 2
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Sumitomo Pharma America, Inc.362 enrolled92 locationsNCT04988555
Recruiting
Not Applicable
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
Acute Lymphoblastic Leukemia
PETHEMA Foundation300 enrolled108 locationsNCT04179929